Kardio Brynow Sp. z o.o. — Clinical Trial Site

17 Registered trials

7 Currently recruiting

Organisation

Kardio Brynow Sp. z o.o.

Location

Katowice, Poland

Identifier

ORG-100046211

Address

Ul. Rolna 17/4-5, 40-555, Poland

Departments

3019:Cardiology
Klinika Kardiologii
n/a
NA
Nie dotyczy / Not applicable

Clinical trials at this site (17)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non… Recruiting

2024-515125-28-00 Non-obstructive hypertrophic cardiomyopathy 4 2025-12-08
A Phase 2 Study of the Effects and Safety of PF-07328948 in Adults with Heart Failure (BRANCH-HF) Recruiting

2024-518438-94-00 Heart failure 4 2025-10-24
A trial to test the effect of obicetrapib/ezetimibe on coronary plaque characteristics on coronary computerized tomography angiography in pe… Recruiting

2023-508475-36-00 Atherosclerotic Cardiovascular Disease 5 2024-10-29
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit… Recruiting

2023-504835-42-00 Heart Failure (Heart Failure with Reduced Ejection Frac 4 2024-02-29
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo… Recruiting

2023-508963-58-00 Symptomatic hypertrophic cardiomyopathy (HCM) 4 2022-01-31
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended

2023-505797-15-00 SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY 5 2024-09-13
A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74) Ended

2023-509747-27-00 Heart failure 4 2023-05-18
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended

2023-506352-24-00 Non-obstructive Hypertrophic Cardiomyopathy 5 2023-04-13
Multiple Dose Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of MYK-224 in Participants with Sympto… Ended

2023-508831-29-00 Symptomatic Hypertrophic Cardiomyopathy and Left Ventri 4 2023-02-15
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY… Ended

2022-502858-14-00 Hypertrophic cardiomyopathy 5 2019-09-05
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended

2022-502316-36-00 Symptomatic Obstructive Hypertrophic Cardiomyopathy 11